Condition: Psoriasis Vulgaris · Sponsor: University Hospital, Ghent
Biologics are effective agents for the treatment of psoriasis. The newest generation of biologics block interleukin 17 and 23. Physicians always prescribe these drugs in a fixed dose, but this may lead to under- and overdosing in some patients. Underdosing may lead to inadequate response or loss of response over time. Overdosage, on the other hand, can lead to higher risk of side effects and higher costs for the healthcare system. In daily clinical practice, physicians often tackle this real-world issue by blind trial- and- error dose modifications or switching to another biologic. In this study, we want to rationalize these dose modifications and optimize dosing based on the drug concentrations, measured in the blood of the patient (i.e. therapeutic drug monitoring). Depending on the drug concentration, the interval between injections will be lengthened or shortened with the aim to reach the required drug concentration to reach the best clinical result. The trial will be conducted in 14 Belgian hospitals where patients will be divided into 2 study groups: a group that will be advised on the dosing scheme of their biologic based on the measured drug concentration and a group that continues dosing as in daily clinical practice. We will monitor if the clinical response and quality of life remains stable. With this study, we will track drug concentrations as we believe that they can guide dosing of biologics and we hope to achieve better safety, lower healthcare expenses and hig…
This description comes directly from the study's public registry record.
Jo Lambert, Prof · 093322298 · jo.lambert@uzgent.be
Rani Soenen, Dr. · 093326541 · rani.soenen@uzgent.be
Always discuss trial participation with your own doctor first.
| AZ Sint-Jan | Bruges, Belgium | Recruiting |
| CHU Saint-Pierre | Brussels, Belgium | Recruiting |
| UCL Saint-Luc | Brussels, Belgium | Active Not Recruiting |
| ULB Erasme | Brussels, Belgium | Not Yet Recruiting |
| UZ Brussel | Brussels, Belgium | Recruiting |
| Grand Hôpital de Charleroi | Charleroi, Belgium | Active Not Recruiting |
| AZ Alma | Eeklo, Belgium | Recruiting |
| Dermatologiepraktijk huidziekten Geel | Geel, Belgium | Recruiting |
| AZ Maria Middelares | Ghent, Belgium | Recruiting |
| UZ Gent | Ghent, Belgium | Recruiting |
| Clinique André Renard | Herstal, Belgium | Withdrawn |
| Dermatologie Handelskaai | Kortrijk, Belgium | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06398106